Commentaries on the life and reign of Charles the First, king of England.

Mode of access: Internet.

De Rebus, Emmanuelis regis Lusitaniae invictissimi virtute et auspicio gesti libri duodecim

História do reinado de D. Manuel I escrita pelo bispo de Silves, Jerônimo Osório, foi publicada pela primeira vez em 1571, em Lisboa. Esta edição de Colônia é a terceira, de 1581, em excelente estado. A obra tornou-se clássica e teve edições em francês e inglês. Somente saindo em português em 1804.

Por um beijo : um acto em verso /

Mode of access: Internet.

Annotações á enormissima sentença que sobre o supposto crime de lesa magestade de primeira cabeça foi proferida na cidade do Porto no dia 21 d'agosto de 1829.

Against the marquis of Palmella and others.

Don Miguel Ier.

"Août 1828."

A tomada de Santarem por D. Affonso Henriques, ou, O captivo de Abzechri : drama em 3 actos e 6 quadros /

Mode of access: Internet.

Ensaio politico sobre as causas que prepararão a usurpação do infante d. Miguel no anno de 1828, e com ella a quéda da carta constitucional do anno 1826.

Mode of access: Internet.

Biography of the principal sovereigns of Europe who have reigned since the French Revolution : adorned with portraits of Their Majesties the King of Great Britain, the Emperors and Empresses of Austria and Russia, the Kings of Bavaria, Denmark, France, Netherlands, Portugal, Prussia, Sardinia, Saxony, Spain, Sweden, Two Sicilies, Wurtemberg, and the Grand Signior.

Mode of access: Internet.

Letter from Sir Joseph de Cancy, knight of the Hospital of St. John of Jerusalem, to King Edward I. (1281), and Letter from King Edward I, to Sir Joseph (1282).

Mode of access: Internet.

Charles I. in 1646. Letters of King Charles the First to Queen Henrietta Maria.

Mode of access: Internet.

Diary and correspondence of John Evelyn, F.R.S., to which is subjoined the private correspondence between King Charles I and Sir Edward Nicholas, and between Sir Edward Hyde, afterwards Earl of Clarendon, and Sir Richard Browne.

Half-title of v. 4: Bohn's historical library.

Stratigraphic micropalaeontology of the Upper Jurassic Neritic formations of Portugal and its Tethyan context. I - The Algarve Basin

Publicações inserida na colecção Memórias Geológicas, nº 35

King of the Renaissance: Art and Politics at the Neapolitan Court of Ferrante I, 1458-1494

In the second half of the fifteenth century, King Ferrante I of Naples (r. 1458-1494) dominated the political and cultural life of the Mediterranean world. His court was home to artists, writers, musicians, and ambassadors from England to Egypt and everywhere in between. Yet, despite its historical importance, Ferrante’s court has been neglected in the scholarship. This dissertation provides a long-overdue analysis of Ferrante’s artistic patronage and attempts to explicate the king’s specific role in the process of art production at the Neapolitan court, as well as the experiences of artists employed therein. By situating Ferrante and the material culture of his court within the broader discourse of Early Modern art history for the first time, my project broadens our understanding of the function of art in Early Modern Europe. I demonstrate that, contrary to traditional assumptions, King Ferrante was a sophisticated patron of the visual arts whose political circumstances and shifting alliances were the most influential factors contributing to his artistic patronage. Unlike his father, Alfonso the Magnanimous, whose court was dominated by artists and courtiers from Spain, France, and elsewhere, Ferrante differentiated himself as a truly Neapolitan king. Yet Ferrante’s court was by no means provincial. His residence, the Castel Nuovo in Naples, became the physical embodiment of his commercial and political network, revealing the accretion of local and foreign visual vocabularies that characterizes Neapolitan visual culture.

Peftjauawybast, king of Nen-nesut : genealogy, art history, and the chronology of late libyan Egypt

This paper argues in detail for the identification of Peftjauawybast, King of Nen-nesut (fl. 728/720 BC ), with Peftjauawybast, High Priest of Ptah in Memphis (fl. c. 790–780 BC2), known from the Apis stela of year 28 of Shoshenq III. This identification ties in with a significant lowering of the accepted dates for the kings from Shoshenq III, Osorkon III and Takeloth III to Shoshenq V, and the material culture associated with them. Such a shift seems to be supported by stylistic and genealogical evidence. As a consequence, it is further suggested that the Master of Shipping at Nen-nesut, Pediese i, was perhaps related by descent and marriage to the family of the High Priests of Memphis and King Peftjauawybast.

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Background: RAS is mutated (RASMT) in ~55% of mCRC, and phase III studies have shown that patients harbouring RAS mutations do not benefit from anti-EGFR MoAbs. In addition, ~50% of RAS Wild Type (RASWT) will not benefit from the addition of an EGFR MoAb to standard chemotherapy. Hence, novel treatment strategies are urgently needed for RASMT and > 50% of RASWT mCRC patients. c-MET is overexpressed in ~50-60%, amplified in ~2-3% and mutated in ~3-5% of mCRC. Recent preclinical studies have shown that c-MET is an important mediator of resistance to MEK inhibitors (i) in RASMT mCRC, and that combined MEKi/METi resulted in synergistic reduction in tumour growth in RASMT xenograft models (1). A number of recent studies have highlighted the role of c-MET in mediating primary/secondary resistance to anti-EGFR MoAbs in mCRC, suggesting that patient with RASWT tumours with aberrant c-MET (RASWT/c-MET+) may benefit from anti-c-MET targeted therapies (2). These preclinical data supported the further clinical evaluation of combined MEKi/METi treatment in RASMT and RASWT CRC patients with aberrant c-MET signalling (overexpression, amplification or mutation; RASWT/c-MET+). Methods: MErCuRIC1 is a phase I combination study of METi crizotinib with MEKi PD-0325901. The dose escalation phase, utilizing a rolling six design, recruits 12-24 patients with advanced solid tumours and aims to assess safety/toxicity of combination, recommended phase II (RPII) dose, pharmacokinetics (PK) and pharmacodynamics (PD) (pERK1/2 in PBMC and tumour; soluble c-MET). In the dose expansion phase an additional 30-42 RASMT and RASWT/c-MET mCRC patients with biopsiable disease will be treated at the RPII dose to further evaluate safety, PK, PD and treatment response. In the dose expansion phase additional biopsy and blood samples will be obtained to define mechanisms of response/resistance to crizotinib/PD-0325901 therapy. Enrolment into the dose escalation phase began in December 2014 with cohort 1 still ongoing. EudraCT registry number: 2014-000463-40. (1) Van Schaeybroeck S et al. Cell Reports 2014;7(6):1940-55; (2) Bardelli A et al. Cancer Discov 2013;3(6):658-73. Clinical trial information: 2014-000463-40.